pharma · Solid Tumors, Colorectal Cancer and Breast Cancer · HER2 Mutant Non-small Cell Lung Cancer · ELVN
Enliven Therapeutics
Enliven Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2019
- Employees
- 75
- Programs
- 6
- Drugs
- 13
- Patents
- 5
Enliven Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Enliven Therapeutics.
Enliven Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
Enliven Therapeutics
Chronic myeloid leukemia
1 trial -
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia
1 trial -
ELVN-001
Enliven Therapeutics
CML (Chronic Myelogenous Leukemia)
1 trial -
ELVN-002
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer
1 trial -
ELVN-002
Enliven Therapeutics
HER2-positive Breast Cancer
1 trial
Frequently asked questions
How many clinical projects does Enliven Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.